Amniox Medical Products Get American Podiatric Medical Association Seal of Approval

Marietta, Ga.-based Amniox Medical Inc., an orthopedic and wound care technology company that makes restorative therapies processed from amniotic membrane and umbilical cord, has been granted the Seal of Approval from the American Podiatric Medical Association (APMA) for its Neox Wound Matrix and Clarix Regenerative Matrix product lines.

The Neox Wound Matrix is indicated for use as a wound covering for dermal ulcers and defects, and is made from cryopreserved human amniotic membrane and umbilical cord. The Clarix Regenerative Matrix is indicated for use as a surgical covering, wrap or barrier. It modulates a local wound environment to simulate fetal scarless healing. Clarix is a bioactive matrix, and it contains matrix proteins to regulate inflammation and prevent scar formation that may lead to limited functional recovery, poorcosmesis, and subsequent surgery or medical management.

As part of its mission, APMA strives to provide reliable information about the quality and effectiveness of available products and therapies to clinicians and patients. The APMA Seal of Approval is granted to products found to promote good foot health.

“The APMA Seal of Approval is awarded after a rigorous scientific review by a group of APMA member podiatrists. The committee examines information about the product’s safety, quality control, and other data,” said APMA Executive Director and CEO Glenn B. Gastwirth, DPM. “Amniox Medical’s Neox and Clarix have received the APMA Seal of Approval in recognition of their value and benefit as part of a wound care regimen overseen by a podiatric physician.”

Amniox Medical is the only provider of a human tissue matrix composed of both amniotic membrane and umbilical cord. These placental tissues have innate regenerative properties that can be preserved and transplanted to other environments. The company’s amniotic membrane/umbilical cord matrix comprises key proteins, cytokines and growth factors that have been shown to modulate inflammation and promote regeneration of normal tissue. Amniox utilizes its proprietary Cryotek process, a cryopreservation technology, to preserve the natural biological and structural integrity of these tissues.

“We are very proud to have our entire product offering recognized by APMA,” said Aaron Smith, general manager of Amniox Medical. “We know that APMA performs a rigorous review of any product under consideration for its Seal of Approval and are honored by their recognition of the safety, quality and extensive scientific evidence supporting our products.”